• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Vivendy Therapeutics

edit

Vivendy Therapeutics Ltd. has developed a specific recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS) that is specifically modified to improve enzyme activity - enhancing the efficacy of the therapy in MPS IVA significantly

Milestones

edit

• 
  Vivendy Therapeutics added Dr. Florian Fischer as CFO.
  Posted 6/19/09 at 5:30am
• 
  Vivendy Therapeutics added Dr. Gertrud Thormann-Huber as Director Clinical and Regulatory Affairs.
  Posted 6/19/09 at 5:30am
• 
  Vivendy Therapeutics added Dr.Gosse Bruinsma as Executive Director.
  Posted 6/19/09 at 5:30am
• 
  Vivendy Therapeutics received $30.5M in Unattributed funding. (1/1/08)
  Posted 6/19/09 at 5:30am

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/19/09

Sources

1. Capital Funding Report [edit]